DUBLIN–(BUSINESS WIRE)–The “Global
Spinal Muscular Atrophy Market (By Drugs – Spinraza, Branaplam &
Reldesemtiv; By Region – North America & Europe) Market Outlook 2025”
report has been added to ResearchAndMarkets.com’s
offering.
Expected approval of gene therapy for treatment of spinal muscular
atrophy is set to emerge as the game-changer in global spinal muscular
atrophy therapeutics market. FDA approval of Zolgensma, experimental
gene therapy by Novartis is awaited in the first half of the year 2019.
It would provide a cost-effective alternative to expensive Spinraza
therapy.
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects
the part of central nervous system which controls voluntary muscle
movements. It is progressive hereditary neuromuscular disorder with
various degrees of severity resulting in respiratory and mobility
impairment. It is caused due to loss of specialized nerve cells, called
motor neurons, in the spinal cord and brainstem. SMA can be categorized
into four sub-types on the basis of severity – Type I or Infantile, Type
II or Intermediate, Type III or Juvenile and Type IV or Adult. SMA type
1 is the most severe form with highest mortality rate.
SMA patients had no treatment option previously prior to approval of the
drug SPINRAZA which is the first and only therapy approved to treat SMA.
There are several therapy in clinical trial phase which is expected to
get approval soon. Growth of global spinal muscular atrophy market is
propelled by the prevalence of spinal muscular atrophy, government
impetus, growing consumer awareness and increasing funding for R&D.
However, the market faces several challenges due to the high cost of
treatment and lower market penetration of drug therapy for the treatment
of SMA.
Global Spinal Muscular Atrophy Market Outlook 2025 provides in-depth
analysis of the current scenario, detailed market outlook of the global
spinal muscular atrophy market with coverage on major therapeutics such
as Spinraza, Branaplam & Reldesemtiv. Future forecasts of spinal
muscular atrophy market overall and across various sub-segments till
2025 is provided in the report. Furthermore, major industry players have
been prudently analysed in the competitive landscape section of the
report in order to provide key comparative insights.
Major industry players operating in the global spinal muscular atrophy
market include Biogen Inc., Cytokinetics Inc., AveXis Inc., F. Hoffman
-La Roche & Ionis Pharmaceuticals Inc., among others. These players are
profiled herein based on attributes such as business overview, product
segments and financial analysis. It also compiles performance comparison
of aforementioned companies and other leading companies in the segment
based on various parameters in the competitive landscape section. In
totality, the report provides detailed market analysis, with relevant
forecasted data supported by key market dynamics. This information will
be helpful in evaluating opportunities in the global spinal muscular
atrophy market.
Market Segments
- Spinraza
- Branaplam
- Reldesemtiv
Key Vendors
- Biogen Inc.
- Cytokinetics Inc.
- AveXis Inc.
- F. Hoffman -La Roche
- Ionis Pharmaceuticals Inc.
Key Topics Covered:
1. Executive Summary
2. Research Methodology
3. Spinal Muscular Atrophy
3.1 Overview
3.1.1 Types of Diseases
3.1.2 Symptoms of SMA
3.1.3 Diagnosis of SMA
3.2 Therapy for SMA
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.1.1 Market Sizing by Value (Actual & Forecasted)
4.1.2 Market Sizing by Volume (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease Type
4.2.2 Market Share by Route of Administration
4.2.3 Market Share by Region
4.2.4 Market Share by Patient Age-Group
5. Market Segmentation by Drugs
5.1 Spinraza
5.2 Branaplam
5.3 Reldesemtiv
6. Regional Analysis
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Gene Therapy for Treatment of Spinal Muscular Atrophy
7.1.2 MRI for SMA Detection
7.1.3 Strategic Collaboration to Develop Novel Small Molecule RNA
Splicing Modifiers
7.2 Growth Drivers
7.2.1 Rising Incidences of Spinal Muscular Atrophy (SMA)
7.2.2 Government Impetus
7.2.3 Growing Consumer Awareness
7.2.5 Increasing Funding for R&D
7.3 Challenges
7.3.1 High Cost of Therapy
7.3.2 Low Market Penetration of Drug Therapy
8. Competitive Landscape
9. Company Profiles
9.1 Biogen Inc.
9.2 Cytokinetics, Inc.
9.3 AveXis, Inc.(Novartis AG)
9.4 F. Hoffmann-La Roche AG
9.5 Ionis Pharmaceuticals, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/fsv4x3/global_spinal?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs , Musculoskeletal
Disorders Drugs